{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:54:57Z","timestamp":1790747697759,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To examine associations of metabolic dysfunction-associated steatotic liver disease (MASLD) and significant fibrosis with glomerular hyperfiltration (GHF) defined from indexed estimated glomerular filtration rate (eGFR), accounting for body size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 9,140 NHANES participants and 721 adults from a Chinese clinical study. Liver phenotypes were G1 (no steatosis\/no significant fibrosis), G2 (MASLD without significant fibrosis), and G3 (MASLD with significant fibrosis). Primary GHF was indexed eGFR above the survey-weighted age- and sex-specific 95th percentile of a low-risk NHANES reference, applied unchanged to both studies. BMI-adjusted Model 3 was central; metabolic adjustment and alternative GHF definitions were sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In NHANES Model 3, G2 and G3 had higher odds of GHF than G1 (OR 2.19, 95% CI 1.57\u20133.07; OR 2.46, 1.51\u20134.00), whereas G3 did not differ from G2 (OR 1.12, 0.74\u20131.70). In the identical fasting subsample, further metabolic adjustment attenuated G2 and G3 versus G1 (OR 1.94 and 2.08), while G3 versus G2 remained near the null. In China, G2 versus G1 was null, whereas G3 had higher odds than G1 and G2; however, G3 included only 29 participants and 8 events. NHANES findings were generally robust to indexed P90, age\/sex\/BSA-residual, and de-indexed sensitivity definitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In NHANES, MASLD phenotypes were associated with higher odds of GHF after accounting for body size, whereas significant fibrosis showed no clear incremental association beyond MASLD. The fibrosis-related association observed in the Chinese clinical study should be interpreted cautiously because of the small G3 subgroup and cross-population differences in GHF calibration. Prospective studies using measured GFR are needed to clarify the temporal and prognostic significance of GHF in MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1944355","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:37Z","timestamp":1790744197000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations of metabolic dysfunction-associated steatotic liver disease and significant fibrosis phenotypes with glomerular hyperfiltration defined by indexed eGFR"],"prefix":"10.3389","volume":"13","author":[{"given":"Wen","family":"Tian","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]},{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiameng","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]},{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]},{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.2337\/dc15-1182","article-title":"Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities","volume":"39","author":"Musso","year":"2016","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","article-title":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study","volume":"67","author":"Sinn","year":"2017","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: definitions, mechanisms and clinical implications","volume":"8","author":"Helal","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2215\/CJN.03080314","article-title":"A systematic review of glomerular hyperfiltration assessment and definition in the medical literature","volume":"10","author":"Cachat","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.2337\/dc11-2189","article-title":"Glomerular hyperfiltration and renal disease progression in type 2 diabetes","volume":"35","author":"Ruggenenti","year":"2012","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","article-title":"Single-nephron glomerular filtration rate in healthy adults","volume":"376","author":"Denic","year":"2017","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/jcm10081717","article-title":"Non-alcoholic fatty liver disease is associated with kidney glomerular hyperfiltration in adults with metabolic syndrome","volume":"10","author":"Abbate","year":"2021","journal-title":"J Clin Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"15837","DOI":"10.3390\/ijms242115837","article-title":"Glomerular hyperfiltration: a marker of fibrosis severity in metabolic associated steatotic liver disease in an adult population","volume":"24","author":"Dalbeni","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/jpm12071142","article-title":"Increased risk of NAFLD in adults with glomerular hyperfiltration: an 8-year cohort study based on 147,162 Koreans","volume":"12","author":"Koo","year":"2022","journal-title":"J Pers Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.2215\/CJN.05050610","article-title":"Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis","volume":"5","author":"Targher","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.metabol.2010.07.022","article-title":"Nonalcoholic steatohepatitis and increased risk of chronic kidney disease","volume":"60","author":"Yasui","year":"2011","journal-title":"Metabolism"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jhep.2017.09.020","article-title":"Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes","volume":"68","author":"Yeung","year":"2017","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.ackd.2017.10.007","article-title":"Kidney function in obesity-challenges in indexing and estimation","volume":"25","author":"Chang","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/ndt\/gfh983","article-title":"Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example","volume":"20","author":"Delanaye","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"F817","DOI":"10.1152\/ajprenal.2000.278.5.F817","article-title":"Glomerular hemodynamics in severe obesity","volume":"278","author":"Chagnac","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/j.ajkd.2010.03.017","article-title":"Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population","volume":"56","author":"Wuerzner","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.kint.2025.02.025","article-title":"Age- and sex-specific reference values of estimated glomerular filtration rate for European adults","volume":"107","author":"Astley","year":"2025","journal-title":"Kidney Int"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/ndt\/gfr651","article-title":"Glomerular hyperfiltration in prediabetes and prehypertension","volume":"27","author":"Okada","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1080\/13813455.2020.1745851","article-title":"Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches","volume":"128","author":"Sharma","year":"2022","journal-title":"Arch Physiol Biochem"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s10620-025-08893-4","article-title":"Advanced liver fibrosis impairs cardiorespiratory fitness in patients with metabolic dysfunction-associated steatotic liver disease","volume":"70","author":"Sogbe","year":"2025","journal-title":"Dig Dis Sci"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1944355\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:38Z","timestamp":1790744198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1944355\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":52,"alternative-id":["10.3389\/fnut.2026.1944355"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1944355","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1944355"}}